nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ALB—acquired immunodeficiency syndrome	0.163	1	CbGaD
Erlotinib—UGT1A1—Abacavir—acquired immunodeficiency syndrome	0.0653	0.116	CbGbCtD
Erlotinib—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.0288	0.0511	CbGbCtD
Erlotinib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0194	0.0345	CbGbCtD
Erlotinib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0176	0.0312	CbGbCtD
Erlotinib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0176	0.0312	CbGbCtD
Erlotinib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0168	0.0299	CbGbCtD
Erlotinib—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0142	0.0252	CbGbCtD
Erlotinib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.013	0.0232	CbGbCtD
Erlotinib—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0128	0.0228	CbGbCtD
Erlotinib—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0128	0.0228	CbGbCtD
Erlotinib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0123	0.0219	CbGbCtD
Erlotinib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0123	0.0219	CbGbCtD
Erlotinib—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0121	0.0215	CbGbCtD
Erlotinib—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0116	0.0206	CbGbCtD
Erlotinib—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0112	0.02	CbGbCtD
Erlotinib—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0111	0.0197	CbGbCtD
Erlotinib—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0108	0.0191	CbGbCtD
Erlotinib—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0106	0.0188	CbGbCtD
Erlotinib—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0106	0.0188	CbGbCtD
Erlotinib—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.00973	0.0173	CbGbCtD
Erlotinib—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.00973	0.0173	CbGbCtD
Erlotinib—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00955	0.017	CbGbCtD
Erlotinib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.00935	0.0166	CbGbCtD
Erlotinib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.00935	0.0166	CbGbCtD
Erlotinib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.00925	0.0165	CbGbCtD
Erlotinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00923	0.0164	CbGbCtD
Erlotinib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.00896	0.0159	CbGbCtD
Erlotinib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0087	0.0155	CbGbCtD
Erlotinib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0087	0.0155	CbGbCtD
Erlotinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00835	0.0149	CbGbCtD
Erlotinib—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.008	0.0142	CbGbCtD
Erlotinib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00787	0.014	CbGbCtD
Erlotinib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00787	0.014	CbGbCtD
Erlotinib—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00724	0.0129	CbGbCtD
Erlotinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00721	0.0128	CbGbCtD
Erlotinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.007	0.0124	CbGbCtD
Erlotinib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00679	0.0121	CbGbCtD
Erlotinib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00659	0.0117	CbGbCtD
Erlotinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00633	0.0113	CbGbCtD
Erlotinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00633	0.0113	CbGbCtD
Erlotinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00607	0.0108	CbGbCtD
Erlotinib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00596	0.0106	CbGbCtD
Erlotinib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00596	0.0106	CbGbCtD
Erlotinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00588	0.0105	CbGbCtD
Erlotinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00553	0.00984	CbGbCtD
Erlotinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00553	0.00984	CbGbCtD
Erlotinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.005	0.0089	CbGbCtD
Erlotinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.005	0.0089	CbGbCtD
Erlotinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00469	0.00835	CbGbCtD
Erlotinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00432	0.00768	CbGbCtD
Erlotinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00419	0.00746	CbGbCtD
Erlotinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00379	0.00674	CbGbCtD
Erlotinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00379	0.00674	CbGbCtD
Erlotinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00364	0.00647	CbGbCtD
Erlotinib—ORM1—saliva—acquired immunodeficiency syndrome	0.00195	0.0255	CbGeAlD
Erlotinib—FLT3—blood plasma—acquired immunodeficiency syndrome	0.00175	0.0229	CbGeAlD
Erlotinib—STK10—blood plasma—acquired immunodeficiency syndrome	0.00117	0.0153	CbGeAlD
Erlotinib—UGT1A1—blood plasma—acquired immunodeficiency syndrome	0.0011	0.0145	CbGeAlD
Erlotinib—NR1I2—digestive system—acquired immunodeficiency syndrome	0.00107	0.014	CbGeAlD
Erlotinib—LTK—lung—acquired immunodeficiency syndrome	0.00089	0.0117	CbGeAlD
Erlotinib—PIP4K2C—retina—acquired immunodeficiency syndrome	0.000865	0.0113	CbGeAlD
Erlotinib—JAK3—lymphoid tissue—acquired immunodeficiency syndrome	0.000863	0.0113	CbGeAlD
Erlotinib—JAK3—digestive system—acquired immunodeficiency syndrome	0.000852	0.0112	CbGeAlD
Erlotinib—ULK3—retina—acquired immunodeficiency syndrome	0.000826	0.0108	CbGeAlD
Erlotinib—JAK3—blood—acquired immunodeficiency syndrome	0.000812	0.0106	CbGeAlD
Erlotinib—MKNK1—retina—acquired immunodeficiency syndrome	0.000777	0.0102	CbGeAlD
Erlotinib—TNK1—blood—acquired immunodeficiency syndrome	0.000745	0.00977	CbGeAlD
Erlotinib—JAK3—lung—acquired immunodeficiency syndrome	0.000712	0.00932	CbGeAlD
Erlotinib—AURKC—nervous system—acquired immunodeficiency syndrome	0.000712	0.00932	CbGeAlD
Erlotinib—TNK1—vagina—acquired immunodeficiency syndrome	0.000691	0.00905	CbGeAlD
Erlotinib—AURKC—central nervous system—acquired immunodeficiency syndrome	0.000685	0.00898	CbGeAlD
Erlotinib—FLT3—lymphoid tissue—acquired immunodeficiency syndrome	0.000681	0.00892	CbGeAlD
Erlotinib—JAK3—nervous system—acquired immunodeficiency syndrome	0.000659	0.00864	CbGeAlD
Erlotinib—EPHA6—nervous system—acquired immunodeficiency syndrome	0.000659	0.00864	CbGeAlD
Erlotinib—TNK1—lung—acquired immunodeficiency syndrome	0.000654	0.00856	CbGeAlD
Erlotinib—MAP3K19—lung—acquired immunodeficiency syndrome	0.000647	0.00848	CbGeAlD
Erlotinib—FLT3—blood—acquired immunodeficiency syndrome	0.00064	0.00839	CbGeAlD
Erlotinib—HIPK4—brain—acquired immunodeficiency syndrome	0.000637	0.00835	CbGeAlD
Erlotinib—JAK3—central nervous system—acquired immunodeficiency syndrome	0.000635	0.00831	CbGeAlD
Erlotinib—EPHA6—central nervous system—acquired immunodeficiency syndrome	0.000635	0.00831	CbGeAlD
Erlotinib—LTK—brain—acquired immunodeficiency syndrome	0.00063	0.00826	CbGeAlD
Erlotinib—FLT3—bone marrow—acquired immunodeficiency syndrome	0.00062	0.00812	CbGeAlD
Erlotinib—ABL2—blood—acquired immunodeficiency syndrome	0.000611	0.00801	CbGeAlD
Erlotinib—LTK—lymph node—acquired immunodeficiency syndrome	0.000609	0.00798	CbGeAlD
Erlotinib—MAP3K19—nervous system—acquired immunodeficiency syndrome	0.000599	0.00785	CbGeAlD
Erlotinib—ULK3—digestive system—acquired immunodeficiency syndrome	0.00058	0.0076	CbGeAlD
Erlotinib—PIP4K2C—blood—acquired immunodeficiency syndrome	0.000579	0.00758	CbGeAlD
Erlotinib—MAP3K19—central nervous system—acquired immunodeficiency syndrome	0.000577	0.00756	CbGeAlD
Erlotinib—ABL2—vagina—acquired immunodeficiency syndrome	0.000567	0.00743	CbGeAlD
Erlotinib—FLT3—lung—acquired immunodeficiency syndrome	0.000561	0.00736	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—acquired immunodeficiency syndrome	0.00056	0.00733	CbGeAlD
Erlotinib—PIP4K2C—spinal cord—acquired immunodeficiency syndrome	0.000557	0.0073	CbGeAlD
Erlotinib—MKNK1—lymphoid tissue—acquired immunodeficiency syndrome	0.000553	0.00724	CbGeAlD
Erlotinib—ULK3—blood—acquired immunodeficiency syndrome	0.000552	0.00724	CbGeAlD
Erlotinib—MKNK1—digestive system—acquired immunodeficiency syndrome	0.000546	0.00715	CbGeAlD
Erlotinib—AURKC—brain—acquired immunodeficiency syndrome	0.000544	0.00713	CbGeAlD
Erlotinib—PIP4K2C—vagina—acquired immunodeficiency syndrome	0.000536	0.00703	CbGeAlD
Erlotinib—ABL2—lung—acquired immunodeficiency syndrome	0.000536	0.00702	CbGeAlD
Erlotinib—ULK3—bone marrow—acquired immunodeficiency syndrome	0.000535	0.007	CbGeAlD
Erlotinib—ULK3—spinal cord—acquired immunodeficiency syndrome	0.000532	0.00697	CbGeAlD
Erlotinib—AURKC—lymph node—acquired immunodeficiency syndrome	0.000526	0.00689	CbGeAlD
Erlotinib—EGFR—lung—acquired immunodeficiency syndrome	0.000523	0.00685	CbGeAlD
Erlotinib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000522	0.00684	CbGeAlD
Erlotinib—MKNK1—blood—acquired immunodeficiency syndrome	0.00052	0.00681	CbGeAlD
Erlotinib—ULK3—vagina—acquired immunodeficiency syndrome	0.000512	0.00671	CbGeAlD
Erlotinib—PIP4K2C—lung—acquired immunodeficiency syndrome	0.000507	0.00664	CbGeAlD
Erlotinib—EPHA6—brain—acquired immunodeficiency syndrome	0.000504	0.0066	CbGeAlD
Erlotinib—JAK3—brain—acquired immunodeficiency syndrome	0.000504	0.0066	CbGeAlD
Erlotinib—MKNK1—bone marrow—acquired immunodeficiency syndrome	0.000503	0.00659	CbGeAlD
Erlotinib—MKNK1—spinal cord—acquired immunodeficiency syndrome	0.000501	0.00656	CbGeAlD
Erlotinib—SLK—blood—acquired immunodeficiency syndrome	0.000492	0.00645	CbGeAlD
Erlotinib—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000489	0.0064	CbGeAlD
Erlotinib—JAK3—lymph node—acquired immunodeficiency syndrome	0.000487	0.00638	CbGeAlD
Erlotinib—ULK3—lung—acquired immunodeficiency syndrome	0.000484	0.00634	CbGeAlD
Erlotinib—MKNK1—vagina—acquired immunodeficiency syndrome	0.000482	0.00631	CbGeAlD
Erlotinib—SLK—bone marrow—acquired immunodeficiency syndrome	0.000476	0.00624	CbGeAlD
Erlotinib—SLK—spinal cord—acquired immunodeficiency syndrome	0.000474	0.00621	CbGeAlD
Erlotinib—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000471	0.00617	CbGeAlD
Erlotinib—PIP4K2C—nervous system—acquired immunodeficiency syndrome	0.00047	0.00615	CbGeAlD
Erlotinib—TNK1—brain—acquired immunodeficiency syndrome	0.000463	0.00606	CbGeAlD
Erlotinib—MAP3K19—brain—acquired immunodeficiency syndrome	0.000458	0.006	CbGeAlD
Erlotinib—SLK—vagina—acquired immunodeficiency syndrome	0.000456	0.00598	CbGeAlD
Erlotinib—MKNK1—lung—acquired immunodeficiency syndrome	0.000456	0.00597	CbGeAlD
Erlotinib—STK10—lymphoid tissue—acquired immunodeficiency syndrome	0.000455	0.00596	CbGeAlD
Erlotinib—PIP4K2C—central nervous system—acquired immunodeficiency syndrome	0.000452	0.00592	CbGeAlD
Erlotinib—STK10—digestive system—acquired immunodeficiency syndrome	0.000449	0.00589	CbGeAlD
Erlotinib—ULK3—nervous system—acquired immunodeficiency syndrome	0.000448	0.00588	CbGeAlD
Erlotinib—TNK1—lymph node—acquired immunodeficiency syndrome	0.000447	0.00586	CbGeAlD
Erlotinib—ABL1—retina—acquired immunodeficiency syndrome	0.000441	0.00578	CbGeAlD
Erlotinib—ULK3—central nervous system—acquired immunodeficiency syndrome	0.000432	0.00566	CbGeAlD
Erlotinib—SLK—lung—acquired immunodeficiency syndrome	0.000432	0.00565	CbGeAlD
Erlotinib—STK10—blood—acquired immunodeficiency syndrome	0.000428	0.00561	CbGeAlD
Erlotinib—UGT1A1—digestive system—acquired immunodeficiency syndrome	0.000424	0.00556	CbGeAlD
Erlotinib—MKNK1—nervous system—acquired immunodeficiency syndrome	0.000422	0.00553	CbGeAlD
Erlotinib—STK10—bone marrow—acquired immunodeficiency syndrome	0.000414	0.00543	CbGeAlD
Erlotinib—MKNK1—central nervous system—acquired immunodeficiency syndrome	0.000406	0.00532	CbGeAlD
Erlotinib—UGT1A1—blood—acquired immunodeficiency syndrome	0.000404	0.0053	CbGeAlD
Erlotinib—STK10—vagina—acquired immunodeficiency syndrome	0.000397	0.0052	CbGeAlD
Erlotinib—ABL1—skin of body—acquired immunodeficiency syndrome	0.000387	0.00507	CbGeAlD
Erlotinib—FLT3—lymph node—acquired immunodeficiency syndrome	0.000384	0.00503	CbGeAlD
Erlotinib—MAP2K5—blood—acquired immunodeficiency syndrome	0.000382	0.00501	CbGeAlD
Erlotinib—Vandetanib—ALB—acquired immunodeficiency syndrome	0.000381	0.513	CrCbGaD
Erlotinib—ABL2—brain—acquired immunodeficiency syndrome	0.000379	0.00497	CbGeAlD
Erlotinib—STK10—lung—acquired immunodeficiency syndrome	0.000375	0.00492	CbGeAlD
Erlotinib—EGFR—brain—acquired immunodeficiency syndrome	0.00037	0.00485	CbGeAlD
Erlotinib—MAP2K5—spinal cord—acquired immunodeficiency syndrome	0.000368	0.00483	CbGeAlD
Erlotinib—ABL2—lymph node—acquired immunodeficiency syndrome	0.000367	0.0048	CbGeAlD
Erlotinib—Gefitinib—ALB—acquired immunodeficiency syndrome	0.000362	0.487	CrCbGaD
Erlotinib—PIP4K2C—brain—acquired immunodeficiency syndrome	0.000359	0.0047	CbGeAlD
Erlotinib—EGFR—lymph node—acquired immunodeficiency syndrome	0.000358	0.00469	CbGeAlD
Erlotinib—MAP2K5—vagina—acquired immunodeficiency syndrome	0.000354	0.00464	CbGeAlD
Erlotinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000354	0.00463	CbGeAlD
Erlotinib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000348	0.00456	CbGeAlD
Erlotinib—STK10—nervous system—acquired immunodeficiency syndrome	0.000348	0.00455	CbGeAlD
Erlotinib—PIP4K2C—lymph node—acquired immunodeficiency syndrome	0.000347	0.00454	CbGeAlD
Erlotinib—ULK3—brain—acquired immunodeficiency syndrome	0.000343	0.00449	CbGeAlD
Erlotinib—MAP2K5—lung—acquired immunodeficiency syndrome	0.000335	0.00439	CbGeAlD
Erlotinib—STK10—central nervous system—acquired immunodeficiency syndrome	0.000335	0.00438	CbGeAlD
Erlotinib—ULK3—lymph node—acquired immunodeficiency syndrome	0.000331	0.00434	CbGeAlD
Erlotinib—CYP1B1—skin of body—acquired immunodeficiency syndrome	0.000328	0.00429	CbGeAlD
Erlotinib—MKNK1—brain—acquired immunodeficiency syndrome	0.000323	0.00423	CbGeAlD
Erlotinib—ABL1—lymphoid tissue—acquired immunodeficiency syndrome	0.000313	0.00411	CbGeAlD
Erlotinib—SLCO2B1—digestive system—acquired immunodeficiency syndrome	0.000312	0.00409	CbGeAlD
Erlotinib—MKNK1—lymph node—acquired immunodeficiency syndrome	0.000312	0.00408	CbGeAlD
Erlotinib—ORM1—blood—acquired immunodeficiency syndrome	0.00031	0.00407	CbGeAlD
Erlotinib—MAP2K5—nervous system—acquired immunodeficiency syndrome	0.00031	0.00407	CbGeAlD
Erlotinib—ABL1—digestive system—acquired immunodeficiency syndrome	0.00031	0.00406	CbGeAlD
Erlotinib—SLK—brain—acquired immunodeficiency syndrome	0.000306	0.004	CbGeAlD
Erlotinib—ORM1—bone marrow—acquired immunodeficiency syndrome	0.0003	0.00394	CbGeAlD
Erlotinib—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000299	0.00392	CbGeAlD
Erlotinib—MAP2K5—central nervous system—acquired immunodeficiency syndrome	0.000299	0.00391	CbGeAlD
Erlotinib—SLK—lymph node—acquired immunodeficiency syndrome	0.000295	0.00387	CbGeAlD
Erlotinib—ABL1—blood—acquired immunodeficiency syndrome	0.000295	0.00386	CbGeAlD
Erlotinib—SLCO2B1—spinal cord—acquired immunodeficiency syndrome	0.000287	0.00376	CbGeAlD
Erlotinib—ABL1—bone marrow—acquired immunodeficiency syndrome	0.000285	0.00374	CbGeAlD
Erlotinib—ABL1—spinal cord—acquired immunodeficiency syndrome	0.000284	0.00372	CbGeAlD
Erlotinib—ABL1—vagina—acquired immunodeficiency syndrome	0.000273	0.00358	CbGeAlD
Erlotinib—ORM1—lung—acquired immunodeficiency syndrome	0.000272	0.00357	CbGeAlD
Erlotinib—STK10—brain—acquired immunodeficiency syndrome	0.000266	0.00348	CbGeAlD
Erlotinib—CYP1B1—lymphoid tissue—acquired immunodeficiency syndrome	0.000265	0.00348	CbGeAlD
Erlotinib—CYP1B1—digestive system—acquired immunodeficiency syndrome	0.000262	0.00344	CbGeAlD
Erlotinib—SLCO2B1—lung—acquired immunodeficiency syndrome	0.000261	0.00342	CbGeAlD
Erlotinib—ABL1—lung—acquired immunodeficiency syndrome	0.000259	0.00339	CbGeAlD
Erlotinib—STK10—lymph node—acquired immunodeficiency syndrome	0.000257	0.00336	CbGeAlD
Erlotinib—ORM1—nervous system—acquired immunodeficiency syndrome	0.000252	0.0033	CbGeAlD
Erlotinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00025	0.00328	CbGeAlD
Erlotinib—CYP1B1—blood—acquired immunodeficiency syndrome	0.00025	0.00327	CbGeAlD
Erlotinib—ORM1—central nervous system—acquired immunodeficiency syndrome	0.000243	0.00318	CbGeAlD
Erlotinib—SLCO2B1—nervous system—acquired immunodeficiency syndrome	0.000242	0.00316	CbGeAlD
Erlotinib—ABL1—nervous system—acquired immunodeficiency syndrome	0.000239	0.00314	CbGeAlD
Erlotinib—MAP2K5—brain—acquired immunodeficiency syndrome	0.000237	0.00311	CbGeAlD
Erlotinib—SLCO2B1—central nervous system—acquired immunodeficiency syndrome	0.000233	0.00305	CbGeAlD
Erlotinib—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000232	0.00304	CbGeAlD
Erlotinib—ABL1—central nervous system—acquired immunodeficiency syndrome	0.000231	0.00302	CbGeAlD
Erlotinib—MAP2K5—lymph node—acquired immunodeficiency syndrome	0.000229	0.003	CbGeAlD
Erlotinib—CYP1B1—lung—acquired immunodeficiency syndrome	0.000219	0.00287	CbGeAlD
Erlotinib—CYP1B1—nervous system—acquired immunodeficiency syndrome	0.000203	0.00266	CbGeAlD
Erlotinib—CYP1B1—central nervous system—acquired immunodeficiency syndrome	0.000195	0.00256	CbGeAlD
Erlotinib—CYP2C8—blood—acquired immunodeficiency syndrome	0.000191	0.00251	CbGeAlD
Erlotinib—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000188	0.00246	CbGeAlD
Erlotinib—ORM1—lymph node—acquired immunodeficiency syndrome	0.000186	0.00244	CbGeAlD
Erlotinib—ABCG2—blood—acquired immunodeficiency syndrome	0.000186	0.00244	CbGeAlD
Erlotinib—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000185	0.00243	CbGeAlD
Erlotinib—SLCO2B1—brain—acquired immunodeficiency syndrome	0.000185	0.00242	CbGeAlD
Erlotinib—ABL1—brain—acquired immunodeficiency syndrome	0.000183	0.0024	CbGeAlD
Erlotinib—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000181	0.00237	CbGeAlD
Erlotinib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.00018	0.00236	CbGeAlD
Erlotinib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000179	0.00235	CbGeAlD
Erlotinib—CYP1A2—blood—acquired immunodeficiency syndrome	0.000179	0.00235	CbGeAlD
Erlotinib—SLCO2B1—lymph node—acquired immunodeficiency syndrome	0.000178	0.00234	CbGeAlD
Erlotinib—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000177	0.00232	CbGeAlD
Erlotinib—ABL1—lymph node—acquired immunodeficiency syndrome	0.000177	0.00232	CbGeAlD
Erlotinib—CYP1A1—blood—acquired immunodeficiency syndrome	0.000177	0.00231	CbGeAlD
Erlotinib—CYP3A5—blood—acquired immunodeficiency syndrome	0.000173	0.00226	CbGeAlD
Erlotinib—ABCG2—vagina—acquired immunodeficiency syndrome	0.000172	0.00226	CbGeAlD
Erlotinib—ALB—brain—acquired immunodeficiency syndrome	0.000169	0.00221	CbGeAlD
Erlotinib—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000164	0.00214	CbGeAlD
Erlotinib—ALB—lymph node—acquired immunodeficiency syndrome	0.000163	0.00214	CbGeAlD
Erlotinib—ABCG2—lung—acquired immunodeficiency syndrome	0.000163	0.00214	CbGeAlD
Erlotinib—CYP3A5—vagina—acquired immunodeficiency syndrome	0.00016	0.0021	CbGeAlD
Erlotinib—CYP1A2—lung—acquired immunodeficiency syndrome	0.000157	0.00206	CbGeAlD
Erlotinib—CYP1B1—brain—acquired immunodeficiency syndrome	0.000155	0.00203	CbGeAlD
Erlotinib—CYP1A1—lung—acquired immunodeficiency syndrome	0.000155	0.00203	CbGeAlD
Erlotinib—CYP3A5—lung—acquired immunodeficiency syndrome	0.000151	0.00198	CbGeAlD
Erlotinib—CYP1B1—lymph node—acquired immunodeficiency syndrome	0.00015	0.00196	CbGeAlD
Erlotinib—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000143	0.00188	CbGeAlD
Erlotinib—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000138	0.00181	CbGeAlD
Erlotinib—ABCB1—retina—acquired immunodeficiency syndrome	0.000137	0.0018	CbGeAlD
Erlotinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000136	0.00178	CbGeAlD
Erlotinib—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000134	0.00175	CbGeAlD
Erlotinib—CYP3A4—blood—acquired immunodeficiency syndrome	0.00013	0.0017	CbGeAlD
Erlotinib—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000128	0.000723	CcSEcCtD
Erlotinib—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.000128	0.000723	CcSEcCtD
Erlotinib—CYP2D6—blood—acquired immunodeficiency syndrome	0.000128	0.00167	CbGeAlD
Erlotinib—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000127	0.000717	CcSEcCtD
Erlotinib—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.000126	0.000715	CcSEcCtD
Erlotinib—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.000126	0.000715	CcSEcCtD
Erlotinib—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000126	0.000715	CcSEcCtD
Erlotinib—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.000126	0.000713	CcSEcCtD
Erlotinib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000126	0.000713	CcSEcCtD
Erlotinib—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000126	0.000712	CcSEcCtD
Erlotinib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000125	0.000708	CcSEcCtD
Erlotinib—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000125	0.000705	CcSEcCtD
Erlotinib—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000124	0.000704	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000124	0.000704	CcSEcCtD
Erlotinib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000124	0.000703	CcSEcCtD
Erlotinib—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000702	CcSEcCtD
Erlotinib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000124	0.000702	CcSEcCtD
Erlotinib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000124	0.000701	CcSEcCtD
Erlotinib—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000123	0.000697	CcSEcCtD
Erlotinib—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000123	0.000697	CcSEcCtD
Erlotinib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000123	0.000697	CcSEcCtD
Erlotinib—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000123	0.000696	CcSEcCtD
Erlotinib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000123	0.000696	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000122	0.000691	CcSEcCtD
Erlotinib—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.00069	CcSEcCtD
Erlotinib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000122	0.000687	CcSEcCtD
Erlotinib—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000121	0.000687	CcSEcCtD
Erlotinib—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000121	0.000686	CcSEcCtD
Erlotinib—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000121	0.000685	CcSEcCtD
Erlotinib—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000121	0.000683	CcSEcCtD
Erlotinib—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000121	0.000682	CcSEcCtD
Erlotinib—Rash—Didanosine—acquired immunodeficiency syndrome	0.00012	0.000681	CcSEcCtD
Erlotinib—Infection—Delavirdine—acquired immunodeficiency syndrome	0.00012	0.000681	CcSEcCtD
Erlotinib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00012	0.00068	CcSEcCtD
Erlotinib—Cough—Ritonavir—acquired immunodeficiency syndrome	0.00012	0.000677	CcSEcCtD
Erlotinib—Headache—Didanosine—acquired immunodeficiency syndrome	0.00012	0.000677	CcSEcCtD
Erlotinib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000119	0.000676	CcSEcCtD
Erlotinib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000119	0.000675	CcSEcCtD
Erlotinib—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000119	0.000674	CcSEcCtD
Erlotinib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000119	0.000673	CcSEcCtD
Erlotinib—CYP2C8—brain—acquired immunodeficiency syndrome	0.000119	0.00156	CbGeAlD
Erlotinib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000119	0.000671	CcSEcCtD
Erlotinib—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000119	0.00067	CcSEcCtD
Erlotinib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000118	0.000667	CcSEcCtD
Erlotinib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000118	0.000666	CcSEcCtD
Erlotinib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000118	0.000666	CcSEcCtD
Erlotinib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000118	0.000665	CcSEcCtD
Erlotinib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000118	0.000664	CcSEcCtD
Erlotinib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000117	0.000663	CcSEcCtD
Erlotinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000117	0.000663	CcSEcCtD
Erlotinib—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000117	0.000661	CcSEcCtD
Erlotinib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000117	0.000661	CcSEcCtD
Erlotinib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000117	0.000661	CcSEcCtD
Erlotinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000117	0.000659	CcSEcCtD
Erlotinib—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000116	0.000659	CcSEcCtD
Erlotinib—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000116	0.000657	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000116	0.000656	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000116	0.000654	CcSEcCtD
Erlotinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000116	0.000654	CcSEcCtD
Erlotinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000116	0.000653	CcSEcCtD
Erlotinib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000115	0.000653	CcSEcCtD
Erlotinib—ABCG2—brain—acquired immunodeficiency syndrome	0.000115	0.00151	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000115	0.000652	CcSEcCtD
Erlotinib—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000652	CcSEcCtD
Erlotinib—Pain—Indinavir—acquired immunodeficiency syndrome	0.000115	0.000648	CcSEcCtD
Erlotinib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000115	0.000648	CcSEcCtD
Erlotinib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000115	0.000648	CcSEcCtD
Erlotinib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000114	0.000644	CcSEcCtD
Erlotinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000114	0.000644	CcSEcCtD
Erlotinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000114	0.000644	CcSEcCtD
Erlotinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000113	0.000642	CcSEcCtD
Erlotinib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000113	0.000642	CcSEcCtD
Erlotinib—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000113	0.000639	CcSEcCtD
Erlotinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000113	0.000638	CcSEcCtD
Erlotinib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.000636	CcSEcCtD
Erlotinib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.000636	CcSEcCtD
Erlotinib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.000636	CcSEcCtD
Erlotinib—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000112	0.000634	CcSEcCtD
Erlotinib—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000634	CcSEcCtD
Erlotinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000112	0.000632	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000112	0.000632	CcSEcCtD
Erlotinib—ABCG2—lymph node—acquired immunodeficiency syndrome	0.000112	0.00146	CbGeAlD
Erlotinib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.00063	CcSEcCtD
Erlotinib—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000627	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.000624	CcSEcCtD
Erlotinib—Shock—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000623	CcSEcCtD
Erlotinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.00011	0.000623	CcSEcCtD
Erlotinib—Cough—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000622	CcSEcCtD
Erlotinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00011	0.000622	CcSEcCtD
Erlotinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000621	CcSEcCtD
Erlotinib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.00062	CcSEcCtD
Erlotinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00011	0.00062	CcSEcCtD
Erlotinib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.00011	0.00062	CcSEcCtD
Erlotinib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.00062	CcSEcCtD
Erlotinib—CYP1A1—brain—acquired immunodeficiency syndrome	0.00011	0.00144	CbGeAlD
Erlotinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000109	0.000618	CcSEcCtD
Erlotinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000109	0.000617	CcSEcCtD
Erlotinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000109	0.000617	CcSEcCtD
Erlotinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.000615	CcSEcCtD
Erlotinib—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000612	CcSEcCtD
Erlotinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000612	CcSEcCtD
Erlotinib—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000108	0.000612	CcSEcCtD
Erlotinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000108	0.000612	CcSEcCtD
Erlotinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000108	0.000611	CcSEcCtD
Erlotinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000108	0.000611	CcSEcCtD
Erlotinib—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.00061	CcSEcCtD
Erlotinib—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000108	0.000608	CcSEcCtD
Erlotinib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000607	CcSEcCtD
Erlotinib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000607	CcSEcCtD
Erlotinib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000607	CcSEcCtD
Erlotinib—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000606	CcSEcCtD
Erlotinib—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000605	CcSEcCtD
Erlotinib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.000604	CcSEcCtD
Erlotinib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.000603	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000603	CcSEcCtD
Erlotinib—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.0006	CcSEcCtD
Erlotinib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000106	0.000599	CcSEcCtD
Erlotinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000106	0.000599	CcSEcCtD
Erlotinib—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000106	0.00139	CbGeAlD
Erlotinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000598	CcSEcCtD
Erlotinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000106	0.000598	CcSEcCtD
Erlotinib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000597	CcSEcCtD
Erlotinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000105	0.000596	CcSEcCtD
Erlotinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000596	CcSEcCtD
Erlotinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000105	0.00138	CbGeAlD
Erlotinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000105	0.000593	CcSEcCtD
Erlotinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000105	0.000593	CcSEcCtD
Erlotinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000592	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000592	CcSEcCtD
Erlotinib—Rash—Stavudine—acquired immunodeficiency syndrome	0.000105	0.000591	CcSEcCtD
Erlotinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.000591	CcSEcCtD
Erlotinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000104	0.000591	CcSEcCtD
Erlotinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000104	0.000589	CcSEcCtD
Erlotinib—Headache—Stavudine—acquired immunodeficiency syndrome	0.000104	0.000587	CcSEcCtD
Erlotinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000104	0.000587	CcSEcCtD
Erlotinib—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.000586	CcSEcCtD
Erlotinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.000586	CcSEcCtD
Erlotinib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000104	0.000586	CcSEcCtD
Erlotinib—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000104	0.00136	CbGeAlD
Erlotinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000103	0.000585	CcSEcCtD
Erlotinib—Rash—Abacavir—acquired immunodeficiency syndrome	0.000103	0.000582	CcSEcCtD
Erlotinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000103	0.000582	CcSEcCtD
Erlotinib—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000582	CcSEcCtD
Erlotinib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000581	CcSEcCtD
Erlotinib—Headache—Abacavir—acquired immunodeficiency syndrome	0.000102	0.000579	CcSEcCtD
Erlotinib—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000578	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000102	0.000577	CcSEcCtD
Erlotinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000102	0.000577	CcSEcCtD
Erlotinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000102	0.000577	CcSEcCtD
Erlotinib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.000573	CcSEcCtD
Erlotinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000101	0.00133	CbGeAlD
Erlotinib—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000572	CcSEcCtD
Erlotinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000571	CcSEcCtD
Erlotinib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.00057	CcSEcCtD
Erlotinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.0001	0.000566	CcSEcCtD
Erlotinib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.0001	0.000566	CcSEcCtD
Erlotinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	9.99e-05	0.000565	CcSEcCtD
Erlotinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	9.99e-05	0.000565	CcSEcCtD
Erlotinib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	9.97e-05	0.00131	CbGeAlD
Erlotinib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	9.91e-05	0.00056	CcSEcCtD
Erlotinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	9.88e-05	0.000559	CcSEcCtD
Erlotinib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	9.86e-05	0.000558	CcSEcCtD
Erlotinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	9.86e-05	0.000558	CcSEcCtD
Erlotinib—Nausea—Stavudine—acquired immunodeficiency syndrome	9.85e-05	0.000557	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	9.83e-05	0.000556	CcSEcCtD
Erlotinib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	9.81e-05	0.000555	CcSEcCtD
Erlotinib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	9.75e-05	0.000552	CcSEcCtD
Erlotinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	9.75e-05	0.00128	CbGeAlD
Erlotinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	9.74e-05	0.000551	CcSEcCtD
Erlotinib—Nausea—Abacavir—acquired immunodeficiency syndrome	9.7e-05	0.000549	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	9.67e-05	0.000547	CcSEcCtD
Erlotinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	9.66e-05	0.000546	CcSEcCtD
Erlotinib—ABCB1—digestive system—acquired immunodeficiency syndrome	9.63e-05	0.00126	CbGeAlD
Erlotinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	9.62e-05	0.000544	CcSEcCtD
Erlotinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	9.62e-05	0.000544	CcSEcCtD
Erlotinib—Pain—Ritonavir—acquired immunodeficiency syndrome	9.58e-05	0.000542	CcSEcCtD
Erlotinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	9.58e-05	0.000542	CcSEcCtD
Erlotinib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	9.58e-05	0.000542	CcSEcCtD
Erlotinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	9.58e-05	0.000542	CcSEcCtD
Erlotinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	9.53e-05	0.000539	CcSEcCtD
Erlotinib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	9.49e-05	0.000537	CcSEcCtD
Erlotinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	9.48e-05	0.000536	CcSEcCtD
Erlotinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	9.38e-05	0.00053	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	9.37e-05	0.00053	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	9.31e-05	0.000527	CcSEcCtD
Erlotinib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	9.31e-05	0.000526	CcSEcCtD
Erlotinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	9.3e-05	0.000526	CcSEcCtD
Erlotinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	9.22e-05	0.000522	CcSEcCtD
Erlotinib—Pain—Saquinavir—acquired immunodeficiency syndrome	9.22e-05	0.000522	CcSEcCtD
Erlotinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	9.17e-05	0.000519	CcSEcCtD
Erlotinib—ABCB1—blood—acquired immunodeficiency syndrome	9.17e-05	0.0012	CbGeAlD
Erlotinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	9.17e-05	0.000519	CcSEcCtD
Erlotinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	9.16e-05	0.000518	CcSEcCtD
Erlotinib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	9.16e-05	0.000518	CcSEcCtD
Erlotinib—Rash—Zidovudine—acquired immunodeficiency syndrome	9.09e-05	0.000514	CcSEcCtD
Erlotinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	9.09e-05	0.000514	CcSEcCtD
Erlotinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	9.08e-05	0.000513	CcSEcCtD
Erlotinib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	9.06e-05	0.000512	CcSEcCtD
Erlotinib—Headache—Zidovudine—acquired immunodeficiency syndrome	9.03e-05	0.000511	CcSEcCtD
Erlotinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	8.96e-05	0.000507	CcSEcCtD
Erlotinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	8.94e-05	0.000506	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	8.88e-05	0.000502	CcSEcCtD
Erlotinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	8.88e-05	0.00116	CbGeAlD
Erlotinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	8.87e-05	0.000502	CcSEcCtD
Erlotinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	8.86e-05	0.000501	CcSEcCtD
Erlotinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	8.86e-05	0.000501	CcSEcCtD
Erlotinib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	8.86e-05	0.000501	CcSEcCtD
Erlotinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	8.84e-05	0.00116	CbGeAlD
Erlotinib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	8.82e-05	0.000499	CcSEcCtD
Erlotinib—Pain—Lamivudine—acquired immunodeficiency syndrome	8.8e-05	0.000498	CcSEcCtD
Erlotinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	8.8e-05	0.000498	CcSEcCtD
Erlotinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	8.69e-05	0.000492	CcSEcCtD
Erlotinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	8.66e-05	0.00049	CcSEcCtD
Erlotinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	8.57e-05	0.000485	CcSEcCtD
Erlotinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	8.56e-05	0.000484	CcSEcCtD
Erlotinib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	8.53e-05	0.000482	CcSEcCtD
Erlotinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	8.53e-05	0.000482	CcSEcCtD
Erlotinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	8.52e-05	0.000482	CcSEcCtD
Erlotinib—ABCB1—vagina—acquired immunodeficiency syndrome	8.5e-05	0.00111	CbGeAlD
Erlotinib—Rash—Indinavir—acquired immunodeficiency syndrome	8.45e-05	0.000478	CcSEcCtD
Erlotinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	8.44e-05	0.000477	CcSEcCtD
Erlotinib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	8.41e-05	0.000476	CcSEcCtD
Erlotinib—Headache—Indinavir—acquired immunodeficiency syndrome	8.4e-05	0.000475	CcSEcCtD
Erlotinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	8.37e-05	0.000474	CcSEcCtD
Erlotinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	8.29e-05	0.000469	CcSEcCtD
Erlotinib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	8.13e-05	0.00046	CcSEcCtD
Erlotinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	8.13e-05	0.00046	CcSEcCtD
Erlotinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	8.05e-05	0.000455	CcSEcCtD
Erlotinib—ABCB1—lung—acquired immunodeficiency syndrome	8.04e-05	0.00105	CbGeAlD
Erlotinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	8.04e-05	0.000455	CcSEcCtD
Erlotinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	8.01e-05	0.000453	CcSEcCtD
Erlotinib—Rash—Efavirenz—acquired immunodeficiency syndrome	7.98e-05	0.000452	CcSEcCtD
Erlotinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	7.98e-05	0.000451	CcSEcCtD
Erlotinib—Nausea—Indinavir—acquired immunodeficiency syndrome	7.96e-05	0.00045	CcSEcCtD
Erlotinib—Headache—Efavirenz—acquired immunodeficiency syndrome	7.93e-05	0.000449	CcSEcCtD
Erlotinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	7.93e-05	0.000448	CcSEcCtD
Erlotinib—CYP2D6—brain—acquired immunodeficiency syndrome	7.91e-05	0.00104	CbGeAlD
Erlotinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	7.74e-05	0.000438	CcSEcCtD
Erlotinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	7.7e-05	0.000436	CcSEcCtD
Erlotinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	7.67e-05	0.000434	CcSEcCtD
Erlotinib—Rash—Delavirdine—acquired immunodeficiency syndrome	7.64e-05	0.000432	CcSEcCtD
Erlotinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	7.63e-05	0.000432	CcSEcCtD
Erlotinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	7.63e-05	0.000431	CcSEcCtD
Erlotinib—Headache—Delavirdine—acquired immunodeficiency syndrome	7.59e-05	0.000429	CcSEcCtD
Erlotinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	7.52e-05	0.000425	CcSEcCtD
Erlotinib—ABCB1—nervous system—acquired immunodeficiency syndrome	7.45e-05	0.000975	CbGeAlD
Erlotinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	7.41e-05	0.000419	CcSEcCtD
Erlotinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	7.38e-05	0.000417	CcSEcCtD
Erlotinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	7.38e-05	0.000417	CcSEcCtD
Erlotinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	7.28e-05	0.000412	CcSEcCtD
Erlotinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	7.2e-05	0.000407	CcSEcCtD
Erlotinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	7.17e-05	0.000939	CbGeAlD
Erlotinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	7.13e-05	0.000403	CcSEcCtD
Erlotinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	7.12e-05	0.000403	CcSEcCtD
Erlotinib—Rash—Ritonavir—acquired immunodeficiency syndrome	7.06e-05	0.0004	CcSEcCtD
Erlotinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	7.06e-05	0.000399	CcSEcCtD
Erlotinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	7.04e-05	0.000398	CcSEcCtD
Erlotinib—Headache—Ritonavir—acquired immunodeficiency syndrome	7.02e-05	0.000397	CcSEcCtD
Erlotinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	6.86e-05	0.000388	CcSEcCtD
Erlotinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.8e-05	0.000385	CcSEcCtD
Erlotinib—Rash—Saquinavir—acquired immunodeficiency syndrome	6.8e-05	0.000385	CcSEcCtD
Erlotinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.79e-05	0.000384	CcSEcCtD
Erlotinib—Headache—Saquinavir—acquired immunodeficiency syndrome	6.76e-05	0.000382	CcSEcCtD
Erlotinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	6.66e-05	0.000376	CcSEcCtD
Erlotinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	6.54e-05	0.00037	CcSEcCtD
Erlotinib—Rash—Lamivudine—acquired immunodeficiency syndrome	6.49e-05	0.000367	CcSEcCtD
Erlotinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	6.48e-05	0.000366	CcSEcCtD
Erlotinib—Headache—Lamivudine—acquired immunodeficiency syndrome	6.45e-05	0.000364	CcSEcCtD
Erlotinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	6.41e-05	0.000362	CcSEcCtD
Erlotinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	6.11e-05	0.000346	CcSEcCtD
Erlotinib—ABCB1—brain—acquired immunodeficiency syndrome	5.69e-05	0.000746	CbGeAlD
Erlotinib—ABCB1—lymph node—acquired immunodeficiency syndrome	5.5e-05	0.00072	CbGeAlD
Erlotinib—EGFR—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	3.71e-05	0.00176	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.68e-05	0.00174	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.68e-05	0.00174	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CXCR4—acquired immunodeficiency syndrome	3.66e-05	0.00173	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	3.63e-05	0.00172	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.61e-05	0.00171	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.61e-05	0.00171	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MBL2—acquired immunodeficiency syndrome	3.57e-05	0.00169	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	3.57e-05	0.00169	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.48e-05	0.00165	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.42e-05	0.00162	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.33e-05	0.00158	CbGpPWpGaD
Erlotinib—EGFR—SHP2 signaling—IL6—acquired immunodeficiency syndrome	3.29e-05	0.00156	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.27e-05	0.00155	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.27e-05	0.00155	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	3.27e-05	0.00155	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	3.24e-05	0.00153	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CCR2—acquired immunodeficiency syndrome	3.18e-05	0.00151	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	3.17e-05	0.0015	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.14e-05	0.00148	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—TAT—acquired immunodeficiency syndrome	3.12e-05	0.00148	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.12e-05	0.00148	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	3.1e-05	0.00147	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	3.1e-05	0.00147	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	3.05e-05	0.00144	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MBL2—acquired immunodeficiency syndrome	3.05e-05	0.00144	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.02e-05	0.00143	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3e-05	0.00142	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3e-05	0.00142	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—TAT—acquired immunodeficiency syndrome	2.91e-05	0.00138	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	2.9e-05	0.00137	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IFNA1—acquired immunodeficiency syndrome	2.87e-05	0.00136	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.8e-05	0.00132	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CCR2—acquired immunodeficiency syndrome	2.8e-05	0.00132	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—ALB—acquired immunodeficiency syndrome	2.79e-05	0.00132	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD79A—acquired immunodeficiency syndrome	2.78e-05	0.00132	CbGpPWpGaD
Erlotinib—ABL2—Axon guidance—IL6—acquired immunodeficiency syndrome	2.75e-05	0.0013	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.74e-05	0.0013	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.73e-05	0.00129	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.73e-05	0.00129	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.72e-05	0.00129	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	2.71e-05	0.00128	CbGpPWpGaD
Erlotinib—EGFR—Disease—APOBEC3G—acquired immunodeficiency syndrome	2.71e-05	0.00128	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.7e-05	0.00128	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.66e-05	0.00126	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.65e-05	0.00126	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TAT—acquired immunodeficiency syndrome	2.65e-05	0.00125	CbGpPWpGaD
Erlotinib—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	2.6e-05	0.00123	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	2.6e-05	0.00123	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.57e-05	0.00121	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.57e-05	0.00121	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ACTG1—acquired immunodeficiency syndrome	2.53e-05	0.0012	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	2.52e-05	0.00119	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CCR5—acquired immunodeficiency syndrome	2.51e-05	0.00119	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.49e-05	0.00118	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	2.48e-05	0.00117	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.47e-05	0.00117	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.47e-05	0.00117	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.47e-05	0.00117	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.45e-05	0.00116	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.43e-05	0.00115	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CCR2—acquired immunodeficiency syndrome	2.39e-05	0.00113	CbGpPWpGaD
Erlotinib—EPHA6—Axon guidance—IL6—acquired immunodeficiency syndrome	2.32e-05	0.0011	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	2.31e-05	0.00109	CbGpPWpGaD
Erlotinib—EGFR—Disease—CCNT1—acquired immunodeficiency syndrome	2.3e-05	0.00109	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.28e-05	0.00108	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD40LG—acquired immunodeficiency syndrome	2.27e-05	0.00107	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—IL2—acquired immunodeficiency syndrome	2.26e-05	0.00107	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AGPS—acquired immunodeficiency syndrome	2.25e-05	0.00106	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.24e-05	0.00106	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD8A—acquired immunodeficiency syndrome	2.24e-05	0.00106	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CSF2—acquired immunodeficiency syndrome	2.24e-05	0.00106	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	2.22e-05	0.00105	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	2.2e-05	0.00104	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.19e-05	0.00104	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.18e-05	0.00103	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ACTG1—acquired immunodeficiency syndrome	2.16e-05	0.00102	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HLA-B—acquired immunodeficiency syndrome	2.16e-05	0.00102	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	2.15e-05	0.00102	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	2.13e-05	0.00101	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	2.12e-05	0.001	CbGpPWpGaD
Erlotinib—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	2.1e-05	0.000993	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.09e-05	0.000989	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MBL2—acquired immunodeficiency syndrome	2.08e-05	0.000983	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.06e-05	0.000974	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.05e-05	0.000971	CbGpPWpGaD
Erlotinib—SLCO2B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.03e-05	0.00096	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	2.01e-05	0.00095	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	1.98e-05	0.000935	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	1.98e-05	0.000935	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.96e-05	0.000929	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.95e-05	0.000924	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.93e-05	0.000916	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.93e-05	0.000916	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.92e-05	0.00091	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	1.9e-05	0.000897	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	1.9e-05	0.000897	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	1.86e-05	0.000881	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.85e-05	0.000878	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.84e-05	0.000869	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TAT—acquired immunodeficiency syndrome	1.79e-05	0.000848	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MBL2—acquired immunodeficiency syndrome	1.78e-05	0.00084	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.76e-05	0.000832	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	1.74e-05	0.000823	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.71e-05	0.000809	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	1.71e-05	0.000808	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.68e-05	0.000797	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	1.68e-05	0.000796	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.68e-05	0.000794	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.66e-05	0.000784	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	1.64e-05	0.000777	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	1.64e-05	0.000774	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	1.63e-05	0.000773	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CCR2—acquired immunodeficiency syndrome	1.63e-05	0.000771	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	1.62e-05	0.000767	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	1.62e-05	0.000765	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	1.61e-05	0.000764	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	1.61e-05	0.000763	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.61e-05	0.000762	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.61e-05	0.000762	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.61e-05	0.00076	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.58e-05	0.000746	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.58e-05	0.000746	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CD4—acquired immunodeficiency syndrome	1.58e-05	0.000746	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.57e-05	0.000743	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	1.56e-05	0.000736	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	1.55e-05	0.000731	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.52e-05	0.000721	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.52e-05	0.000721	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	1.52e-05	0.00072	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.47e-05	0.000697	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IFNA1—acquired immunodeficiency syndrome	1.47e-05	0.000694	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.46e-05	0.00069	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000687	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.45e-05	0.000686	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000684	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	1.44e-05	0.000681	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.43e-05	0.000678	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.43e-05	0.000678	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—IL6—acquired immunodeficiency syndrome	1.43e-05	0.000677	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.43e-05	0.000677	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.43e-05	0.000676	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—ALB—acquired immunodeficiency syndrome	1.43e-05	0.000675	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD79A—acquired immunodeficiency syndrome	1.42e-05	0.000674	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	1.4e-05	0.000661	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CCR2—acquired immunodeficiency syndrome	1.39e-05	0.000659	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	1.39e-05	0.000657	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.38e-05	0.000652	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.36e-05	0.000642	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.35e-05	0.000638	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.35e-05	0.000637	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	1.35e-05	0.000637	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—IL6—acquired immunodeficiency syndrome	1.35e-05	0.000637	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.33e-05	0.000632	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IFNG—acquired immunodeficiency syndrome	1.33e-05	0.000631	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.33e-05	0.000628	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.32e-05	0.000626	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1.32e-05	0.000623	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.3e-05	0.000614	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD4—acquired immunodeficiency syndrome	1.29e-05	0.00061	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IFNA1—acquired immunodeficiency syndrome	1.25e-05	0.000593	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD79A—acquired immunodeficiency syndrome	1.22e-05	0.000576	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.22e-05	0.000576	CbGpPWpGaD
Erlotinib—EGFR—Disease—CXCR4—acquired immunodeficiency syndrome	1.21e-05	0.000572	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.2e-05	0.000568	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.19e-05	0.000564	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL2—acquired immunodeficiency syndrome	1.18e-05	0.000561	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.18e-05	0.000559	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD40LG—acquired immunodeficiency syndrome	1.16e-05	0.000549	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—IL2—acquired immunodeficiency syndrome	1.16e-05	0.000548	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.15e-05	0.000545	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD8A—acquired immunodeficiency syndrome	1.15e-05	0.000543	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CSF2—acquired immunodeficiency syndrome	1.15e-05	0.000543	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.15e-05	0.000543	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.14e-05	0.000541	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.14e-05	0.000539	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.13e-05	0.000536	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000523	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-B—acquired immunodeficiency syndrome	1.1e-05	0.000523	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.09e-05	0.000516	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.08e-05	0.000512	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.08e-05	0.00051	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.07e-05	0.000508	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.02e-05	0.000481	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.95e-06	0.000471	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD40LG—acquired immunodeficiency syndrome	9.92e-06	0.00047	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.85e-06	0.000466	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.82e-06	0.000465	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CSF2—acquired immunodeficiency syndrome	9.81e-06	0.000464	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD8A—acquired immunodeficiency syndrome	9.81e-06	0.000464	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—IL6—acquired immunodeficiency syndrome	9.71e-06	0.00046	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	9.71e-06	0.00046	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CD4—acquired immunodeficiency syndrome	9.67e-06	0.000458	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-B—acquired immunodeficiency syndrome	9.44e-06	0.000447	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	9.29e-06	0.00044	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—IL6—acquired immunodeficiency syndrome	9.17e-06	0.000434	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9e-06	0.000426	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	8.81e-06	0.000417	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TNF—acquired immunodeficiency syndrome	8.59e-06	0.000407	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—acquired immunodeficiency syndrome	8.53e-06	0.000404	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.46e-06	0.000401	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.46e-06	0.000401	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—acquired immunodeficiency syndrome	8.3e-06	0.000393	CbGpPWpGaD
Erlotinib—EGFR—Disease—CCR5—acquired immunodeficiency syndrome	8.28e-06	0.000392	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	7.92e-06	0.000375	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.66e-06	0.000363	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.62e-06	0.000361	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	7.49e-06	0.000355	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TNF—acquired immunodeficiency syndrome	7.34e-06	0.000347	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.01e-06	0.000332	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—acquired immunodeficiency syndrome	6.96e-06	0.00033	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—acquired immunodeficiency syndrome	6.93e-06	0.000328	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IFNG—acquired immunodeficiency syndrome	6.83e-06	0.000323	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD4—acquired immunodeficiency syndrome	6.59e-06	0.000312	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.44e-06	0.000305	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.43e-06	0.000304	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.34e-06	0.0003	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.25e-06	0.000296	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.12e-06	0.00029	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2—acquired immunodeficiency syndrome	6.07e-06	0.000287	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.97e-06	0.000283	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—acquired immunodeficiency syndrome	5.92e-06	0.00028	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IFNG—acquired immunodeficiency syndrome	5.83e-06	0.000276	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.8e-06	0.000275	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	5.69e-06	0.00027	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.67e-06	0.000269	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD4—acquired immunodeficiency syndrome	5.63e-06	0.000267	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ALB—acquired immunodeficiency syndrome	5.44e-06	0.000257	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.33e-06	0.000252	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.23e-06	0.000248	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD4—acquired immunodeficiency syndrome	5.2e-06	0.000246	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—acquired immunodeficiency syndrome	5.18e-06	0.000245	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ALB—acquired immunodeficiency syndrome	5.07e-06	0.00024	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	4.61e-06	0.000218	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.5e-06	0.000213	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.47e-06	0.000212	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.67e-06	0.000174	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—acquired immunodeficiency syndrome	3.57e-06	0.000169	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.35e-06	0.000159	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.33e-06	0.000158	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	3.31e-06	0.000156	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	3.12e-06	0.000148	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—acquired immunodeficiency syndrome	3.05e-06	0.000144	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	2.86e-06	0.000136	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—acquired immunodeficiency syndrome	2.81e-06	0.000133	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	2.49e-06	0.000118	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	2.35e-06	0.000111	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.99e-06	9.43e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.97e-06	9.32e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.54e-06	7.27e-05	CbGpPWpGaD
